Browsing by Author "Baha, Ayse"

Now showing 1 - 4 of 4

The Course of Renal Functions in Copd. Two Statition: Exacerbation and Stable Period
(Wolters Kluwer Medknow Publications, 2019) Baha, Ayse; Ogan, Nalan; Akpinar, Evrim Eylem; Ates, Can; Gulhan, Meral
Objective: Comorbidities in chronic obstructive pulmonary disease (COPD) are important factors that determine the prognosis of the disease. However, there are few studies about renal dysfunction. We aimed to compare the renal functions in COPD patients with stable and exacerbation periods and to determine the frequency of acute renal failure (ARF) during exacerbation. MATERIALS AND METHODS: The files of 320 patients with COPD (forced expiratory volume in 1 s/forced vital capacity <70% in pulmonary function test) who were admitted to our hospital between 2015 and 2016 were evaluated retrospectively. After exclusion criteria, 113 patients were included in the study. Data were analyzed by appropriate statistical method. RESULTS: Ninety (80.4%) of the patients were male and 23 (19.6%) were female. In the exacerbation period, blood urea nitrogen (P < 0.001), creatinine (P < 0.001), white blood cell (P < 0.001), C-reactive protein (P < 0.001), and sedimentation (P < 0.001) were higher than that in the stable period. Furthermore, hemoglobin (P = 0.021) and estimated glomerular filtration rate (eGFR) (P < 0.001) were significantly lower. The number of emergency department admission in patients with eGFR <60 ml/min during the exacerbation more than the patients with eGFR >= 60 ml/min. Twenty (17.7%) patients have developed ARF during exacerbation (eGFR <60 ml/min). CONCLUSION: In COPD exacerbation period, kidney function is affected negatively in most patients (even if it does not reach the ABY border) and tends to improve in the stable period. In patients with COPD, it is thought that the causes of respiratory failure negatively affect renal function.
Do N-Terminal Pro-Brain Natriuretic Peptide Levels Determine the Prognosis of Community Acquired Pneumonia
(Soc Brasileira Pneumologia Tisiologia, 2019) Akpinar, Evrim Eylem; Hosgun, Derya; Akpinar, Serdar; Ates, Can; Baha, Ayse; Gulensoy, Esen Sayin; Ogan, Nalan
Objective: Pneumonia is a leading cause of mortality worldwide, especially in the elderly. The use of clinical risk scores to determine prognosis is complex and therefore leads to errors in clinical practice. Pneumonia can cause increases in the levels of cardiac biomarkers such as N-terminal pro-brain natriuretic peptide (NT-proBNP). The prognostic role of the NT-proBNP level in community acquired pneumonia (CAP) remains unclear. The aim of this study was to evaluate the prognostic role of the NT-proBNP level in patients with CAP, as well as its correlation with clinical risk scores. Methods: Consecutive inpatients with CAP were enrolled in the study. At hospital admission, venous blood samples were collected for the evaluation of NT-proBNP levels. The Pneumonia Severity Index (PSI) and the Confusion, Urea, Respiratory rate, Blood pressure, and age = 65 years (CURB-65) score were calculated. The primary outcome of interest was all-cause mortality within the first 30 days after hospital admission, and a secondary outcome was ICU admission. Results: The NT-proBNP level was one of the best predictors of 30-day mortality, with an area under the curve (AUC) of 0.735 (95% CI: 0.642-0.828; p < 0.001), as was the PSI, which had an AUC of 0.739 (95% CI: 0.634-0.843; p < 0.001), whereas the CURB-65 had an AUC of only 0.659 (95% CI: 0.556-0.763; p = 0.006). The NT-proBNP cut-off level found to be the best predictor of ICU admission and 30day mortality was 1,434.5 pg/mL. Conclusions: The NT-proBNP level appears to be a good predictor of ICU admission and 30-day mortality among inpatients with CAP, with a predictive value for mortality comparable to that of the PSI and better than that of the CURB-65 score.
Evaluation of Copd Patient's Relatives Assessment of Disease Awarness, Load of Care Giving and Loss of Workforce: Turkish Thoracic Society Copd Working Group
(European Respiratory Soc Journals Ltd, 2018) Baha, Ayse; Kokturk, Nurdan; Yildirim, Elif; Ozmen, Ipek; Gurgun, Alev; Topcu, Fusun; Ates, Can
The Evaluation of Disease Awareness, Caregiver Burden, and Workday Loss in Caregivers of Copd Patients
(Tubitak Scientific & Technological Research Council Turkey, 2022) Baha, Ayse; Kokturk, Nurdan; Ozturk, Burcu; Ozari Yildirim, Elif; Ozmen, Ipek; Gurgun, Alev; Ates, Can
Background/aim: Our aim is to determine the caregiver burden of chronic obstructive lung disease (COPD) patient's caregivers, and to determine whether there is a workday loss. Materials and methods: 252 COPD patients and their caregivers were included. Disease information of the patients were recorded and a questionnaire was applied. Socio-demographic characteristics of the caregivers were recorded and a questionnaire consisting of 24 questions including COPD disease, treatment and loss of working days, and the Zarit Scale were used. Results: 128(50.8%) of the patients according to GOLD were group-D, 97(38.5%) of the patient's relatives were working, 62(24.7%) were not able to go to work for 1-14 days, and 125(57.1%) spent outside the home from 1-14 nights, because those accompanied to patients. In univariate analysis were detected modified medical research council (mMRC) (p < 0.001), CAT (p < 0.001), the number of comorbidities of patients (p = 0.027), forced expiratory volume in 1 FEV1cc (p = 0.009), FEV1% (p < 0.001), the presence of long term oxygen therapy (LTOT), and the number of comorbidities of the patient's relatives (p = 0.06) increased the care load. In multiple linear regression analysis, age (p = 0.03), COPD assessment test (CAT) score (p = 0.001), FEV1% (<0.068) and the number of comorbidities of patients (p = 0.01) and the number of comorbidities of caregivers (p = 0.003) increased the caregiving burden. Conclusion: In COPD increases caregiving burden. This burden is greater in symptomatic patients and when comorbidities are present. Psychosocial and legal regulations should be investigated and solutions should be produced for the caregivers of COPD patients.